Clinical Trial Update: Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study of MP-513 as monotherapy or in combination with sulfonylurea in Japanese patients with Type 2 Diabetes Mellitus has completed and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MP-513

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2015-01-02